Researchers have identified Miro1, a protein found at elevated levels in the skeletal muscles of people with Type 2 diabetes, as a potential driver of insulin resistance. The protein sits on the outer membrane of mitochondria and appears to interfere with how muscles respond to insulin.
In preclinical experiments, removing Miro1 restored insulin responsiveness in muscle cells. A randomized controlled trial showed that aerobic exercise reduced Miro1 levels in people with obesity and Type 2 diabetes, alongside improvements in insulin sensitivity and muscle energy production.
The findings were published in Nature Communications. Dr. John P. Kirwan, senior author and now executive director of the OU Health Harold Hamm Diabetes Center at the University of Oklahoma, said the work "identifies Miro1 as a key part of the answer" to understanding insulin resistance. Elizabeth Heintz, the study's first author, is a doctoral candidate at Pennington Biomedical. Christopher Axelrod served as co-corresponding author.
Kirwan stated that the research "opens a path toward treatments that could one day complement" exercise for diabetes management. However, scientists still need to demonstrate whether directly targeting Miro1 can produce safe and effective treatments in humans. The preclinical restoration of insulin responsiveness has not yet been replicated in human trials.
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, the National Center for Complementary and Integrative Health, the National Heart, Lung, and Blood Institute, and the National Institute of General Medical Sciences funded the study.